STOCK TITAN

Portage Biotech Inc - PRTG STOCK NEWS

Welcome to our dedicated page for Portage Biotech news (Ticker: PRTG), a resource for investors and traders seeking the latest updates and insights on Portage Biotech stock.

Portage Biotech Inc (PRTG) is a clinical-stage biopharmaceutical company advancing novel immuno-oncology therapies through strategic research and development. This news hub provides investors and industry observers with timely updates on clinical milestones, partnership announcements, and corporate developments essential for understanding the company's progress in addressing unmet medical needs.

Our curated collection offers comprehensive access to official press releases and verified news coverage related to PRTG's therapeutic pipeline, including combination therapies targeting immune resistance. Users will find updates on clinical proof-of-concept studies, regulatory developments, and strategic collaborations that shape the company's position in the biotech sector.

The resource prioritizes updates across three key areas: clinical trial advancements, research partnerships, and financial disclosures. Each category maintains focus on material developments while avoiding speculative commentary, ensuring users receive actionable information aligned with investment research requirements.

Bookmark this page for streamlined access to Portage Biotech's latest developments in immuno-oncology innovation. Regularly updated content serves as a reliable foundation for monitoring the company's progress through critical clinical and corporate milestones.

Rhea-AI Summary

Pfizer Inc. reported its third-quarter 2022 results, with revenues of $22.6 billion, a 6% decline compared to the previous year. Excluding contributions from Paxlovid and Comirnaty, the revenue showed a 2% operational growth. Reported diluted EPS increased by 6% to $1.51, and adjusted diluted EPS rose 40% to $1.78. The company raised its 2022 revenue guidance to $99.5-$102 billion and narrowed its adjusted diluted EPS guidance to $6.40-$6.50. Pfizer's pipeline includes promising candidates with positive Phase 3 data, and it plans to launch up to 19 new products within 18 months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.5%
Tags
none
-
Rhea-AI Summary

Pfizer has completed its acquisition of Biohaven Pharmaceutical for $11.6 billion, paying $148.50 per share. This acquisition adds the innovative migraine therapy NURTEC® ODT and a portfolio of CGRP receptor antagonists, including rimegepant and zavegepant, to Pfizer's pipeline. These drugs aim to serve over 1 billion migraine patients globally. The merger enhances Pfizer's Internal Medicine portfolio with strong growth potential through 2030 and beyond. Biohaven became a wholly-owned subsidiary, while Biohaven Ltd. retained non-CGRP assets and will continue trading under the ticker BHVN.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.41%
Tags
-
Rhea-AI Summary

Portage Biotech Inc. (PRTG) has outlined its strategic focus on advancing its clinical development programs, specifically targeting immuno-oncology therapies through its iNKT and adenosine platforms. Major goals include converting the PORT-2 study into a company-sponsored trial and launching new studies in the U.S. Clinical trials are set to provide efficacy readouts in multiple tumor types over the next two years. Despite challenges, the company anticipates key data releases through 2024, aiming to expand its pipeline and enhance treatments for cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.86%
Tags
none
Rhea-AI Summary

Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company, has announced its participation in two upcoming investor conferences.

They will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 9:30 am ET and at Cantor Fitzgerald’s Oncology, Hematology, & HemeOnc Conference on September 28, 2022, at 1:45 pm ET. The management will also hold one-on-one meetings with investors at these events, emphasizing their commitment to improving treatment options and survival rates for patients with cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.31%
Tags
conferences
-
Rhea-AI Summary

Portage Biotech (PRTG) reported its financial results for Q2 2022, highlighting significant advancements in its clinical pipeline, including five small molecule immuno-oncology assets. The company extended its cash runway potentially into 2024 following a $30 million share purchase agreement with Lincoln Park Capital Fund. Financially, PRTG reduced its net loss from $3.2 million in Q2 2021 to $1.6 million in Q2 2022 while increasing operating expenses to $4.1 million. Key collaborations with research institutions and promising early data from clinical studies underscore PRTG's growth potential.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.81%
Tags
-
Rhea-AI Summary

Portage Biotech Inc. (NASDAQ: PRTG) has announced leadership changes to strengthen its board. CEO Dr. Ian Walters will additionally serve as Chairman of the Board, while current Chairman Dr. Greg Bailey transitions to lead Director. The company also appointed Justin Fairchild, MPH, as Vice President of Development, enhancing its clinical immunotherapy expertise. These decisions reflect the board's confidence in Walters' leadership amid challenging market conditions as Portage prepares for multiple data readouts over the next year, including ongoing Phase 1/2 studies of innovative treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.21%
Tags
none
Rhea-AI Summary

Portage Biotech Inc. (NASDAQ: PRTG) reported its financial results for FY 2022, with a net loss of approximately $19.2 million, up from $17.2 million in FY 2021. Operating expenses increased to $15.6 million, primarily driven by a rise in general and administrative costs. However, the company has bolstered its pipeline by acquiring four adenosine-targeting assets and extending its cash runway into 2024 through a $30 million share purchase agreement. Portage's promising clinical data, particularly for its PORT-2 study, signifies ongoing progress in immuno-oncology treatment development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Portage Biotech (PRTG) announced its FY 2022 financial results, reporting a net loss of approximately $19.2 million, up from $17.2 million in FY 2021. The company has recently enhanced its portfolio by acquiring four adenosine-targeting assets for about $21 million, potentially extending its cash runway into 2024 via a $30 million share purchase agreement. Despite a decrease in R&D costs to approximately $6.8 million, G&A expenses rose 73% to about $8.8 million. Portage's cash and cash equivalents as of June 30, 2022, were approximately $21 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Portage Biotech has acquired full ownership of iOx Therapeutics Ltd., obtaining the remaining 22% equity in exchange for 1,070,000 shares of Portage stock. This acquisition provides Portage complete rights to the iNKT agonist platform, including lead programs PORT-2 and PORT-3, which aim to enhance immune responses against solid tumors. A potential additional payment of $25 million in shares or cash is tied to a clinical milestone. Preliminary data from these programs is expected by early 2023, underlining Portage's commitment to advancing its immunotherapy portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.13%
Tags
Rhea-AI Summary

Portage Biotech Inc. (PRTG) has acquired Tarus Therapeutics for approximately $21 million, gaining two clinical-stage and two preclinical adenosine compounds. This strategic move aims to enhance immuno-oncology treatments targeting the adenosine pathway, which is crucial in cancer treatment resistance. The deal involves the issuance of 2,425,999 shares and $3 million in liabilities. Additionally, a share purchase agreement with Lincoln Park Capital for up to $30 million is expected to extend Portage's cash runway into 2024. A conference call is scheduled for July 7, 2022, to discuss the acquisition and future plans.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags

FAQ

What is the current stock price of Portage Biotech (PRTG)?

The current stock price of Portage Biotech (PRTG) is $11.03 as of April 29, 2025.

What is the market cap of Portage Biotech (PRTG)?

The market cap of Portage Biotech (PRTG) is approximately 15.0M.
Portage Biotech Inc

NYSE:PRTG

PRTG Rankings

PRTG Stock Data

14.96M
800.06k
51.38%
6.2%
1.06%
Biotechnology
Healthcare
Link
British Virgin Islands
Tortola